Arcturus Therapeutics Holdings Inc

ARCT

6.874USD

-0.206-2.91%

Market hours （ET）Quotes delayed by 15 min

Arcturus Therapeutics Holdings Inc's Score

Industry at a Glance

Industry Ranking

92 / 391

Overall Ranking

207 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Arcturus Therapeutics Holdings Inc Highlights

StrengthsRisks

Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Growing

The company is in a growing phase, with the latest annual income totaling USD 82.03M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 82.03M.

Fairly Valued

The company’s latest PE is -2.81, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 24.41M shares, increasing 0.27% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 14.26K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.56.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

25.273

Target Price

+256.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Arcturus Therapeutics Holdings Inc is 6.16, ranking 282 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 7.20M, representing a year-over-year decrease of 68.39%, while its net profit experienced a year-over-year decrease of 3.09%.

Score

Industry at a Glance

Previous score

6.16

Change

0



Financials

9.19

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.63

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Arcturus Therapeutics Holdings Inc is 7.11, ranking 169 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.81, which is -2402.74% below the recent high of 64.80 and -1268.45% above the recent low of -38.51.

Score

Industry at a Glance

Previous score

7.11

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 92/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Arcturus Therapeutics Holdings Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 21.50, with a high of 68.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Arcturus Therapeutics Holdings Inc is 5.96, ranking 287 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.01 and the support level at 5.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.22

Change

-0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Arcturus Therapeutics Holdings Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.05%, representing a quarter-over-quarter decrease of 4.62%. The largest institutional shareholder is Catherine Wood, holding a total of 2.61M shares, representing 9.19% of shares outstanding, with 24.05% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

4.69M

--

ARK Investment Management LLC

Star Investors

1.87M

+9.19%

BlackRock Institutional Trust Company, N.A.

2.10M

-1.86%

The Vanguard Group, Inc.

Star Investors

1.89M

+4.17%

Amova Asset Management Co., Ltd.

1.95M

+6.30%

Payne (Joseph E)

1.48M

--

Geode Capital Management, L.L.C.

611.82K

+0.91%

State Street Investment Management (US)

1.05M

+2.54%

Dimensional Fund Advisors, L.P.

555.41K

-4.61%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Arcturus Therapeutics Holdings Inc is 2.19, ranking 242 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.49. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Arcturus Therapeutics Holdings Inc

ARCT

6.62 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment